Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-05-27 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2022-05-27 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding a U.S. FDA inspection at the company's manufacturing facility. It mentions the issuance of Form 483 with observations and the company's commitment to address them. The document references compliance with SEBI Listing Obligations Regulation 30, which pertains to disclosure of material events. The document is brief (1943 characters) and serves as an announcement of a regulatory event rather than a detailed report or financial statement. It does not contain financial data, audit results, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) disclosing information about a U.S. FDA inspection at the company's manufacturing facility. It mentions the issuance of Form 483 with observations and the company's response. The document references compliance with SEBI Regulation 30, which pertains to disclosure of material events. The content is an announcement of a regulatory inspection and related observations, not a financial report, audit, or management discussion. The document length is short (2192 characters) and it serves as a regulatory disclosure rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-20 English
Press Release
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received sANDA approval from the U.S. FDA for a specific pharmaceutical product. It is addressed to stock exchanges and includes a media release for immediate distribution. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on a regulatory approval announcement related to the company's product portfolio, which is typical of a Capital/Financing Update or similar category. However, since it is about regulatory approval of a product (not financing or capital structure changes), it does not fit CAP. It is not a regulatory filing or report publication announcement either, as it is a standalone press release. Given the options, the best fit is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories specifically.
2022-05-20 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is an invitation to an earnings call for Glenmark's Q4 FY 2021-22 results. It includes details such as date, time, dial-in numbers, and contact information for clarifications. There is no actual financial data or report content, only an announcement of the call event. Therefore, this document is best classified as a Call Transcript (CT) category, specifically an invitation to a conference call related to earnings results.
2022-05-19 English
Closure of trading window
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 68 characters) and contains no substantive content, financial data, or any report-related information. It only includes a placeholder for an omitted picture and no other text. This does not meet the criteria for any detailed report or announcement. Given the lack of content, the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous or non-informative filings.
2022-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.